Ministry of Health publicises prices of Molnupiravir drugs produced in Việt Nam

February 25, 2022 - 09:08

The cost of the Vietnamese-produced Molnupiravir COVID-19 treatment drugs have been announced.


Illustrative image. — Photo

HÀ NỘI — The cost of the Vietnamese-produced Molnupiravir COVID-19 treatment drugs have been announced.

The Drug Administration of Việt Nam (DAV) under the Ministry of Health (MoH) revealed the set prices of the drugs produced by Vietnamese manufacturers.

One pill of Molravir 400mg made by Boston Vietnam Pharma costs VNĐ11,550 while the prices of Movinavir 200mg manufactured by Mekophar Chemical Pharmaceutical, and Molnupiravir Stella 400mg produced by Stellapharm J.V Co., Ltd. are VNĐ8,675 and VNĐ12,500 a tablet, respectively.

These drugs are sold to COVID-19 patients for home treatment provided that they show proof of being infected with coronavirus and a prescription.  

The Drug Administration of Việt Nam officially licensed the three COVID-19 drugs on February 17.

The DAV requested drug manufacturing and registration establishments to produce in accordance with dossiers and documents registered with the Ministry of Health, coordinate with treatment facilities to strictly comply with current regulations on prescription drugs, monitor the safety, effectiveness, and unwanted effects of drugs on Vietnamese people, and report regularly the findings.

The DAV also asked the departments of health of provinces and centrally-run cities to direct local medical examination and treatment facilities, medical staff, and drug supply establishments to notify patients of the benefits and risks when using these drugs, treatment methods, other drugs that can replace Molnupiravir in treating COVID-19.

During the circulation of the three drugs, based on the monitoring and updating information on the safety and effectiveness of them, the agency may decide to revoke the granted certificates of registration for circulation in line with Clause 1, Article 58 of the Law on Pharmacy.

These drugs are used to treat mild to moderate adult COVID-19 patients with at least one risk factor that could enhance the progression of the disease, according to the MoH.

The drugs should not be used for pregnant women or those who are planning to become pregnant, nursing women, and children. — VNS